deltatrials
Completed PHASE3 NCT00107848

PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

A 1 Year Open Label, Flexible Dosage Extension Study to Assess the Safety and Continued Effectiveness of PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

Sponsor: Cephalon

Conditions Narcolepsy Sleep Apnea, Obstructive
Interventions Modafinil
Updated 7 times since 2017 Last updated: May 8, 2014 Started: Oct 31, 2004 Completion: Sep 30, 2005

A PHASE3 clinical study on Narcolepsy and Sleep Apnea, Obstructive, this trial is completed. The trial is conducted by Cephalon and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cephalon
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Austin, United States, Birmingham, United States, Calgary, Canada, Chevy Chase, United States, Chicago, United States, Cleveland, United States, Columbia, United States, Dallas, United States, Danville, United States and 43 more location s